Protocol Ledger

NCT03819101 · Phase III · RECRUITING

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Interventional Phase III clinical trial protocol NCT03819101 sponsored by Gustave Roussy, Cancer Campus, Grand Paris in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-06 Enrollment: 1,210 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03819101
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,210 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03819101
Protocol FieldVerified Registry Value
NCT IdentifierNCT03819101
Consolidated Lead SponsorGustave Roussy, Cancer Campus, Grand Paris
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,210 participants (ESTIMATED)
Registered Start Date2019-06-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03819101
Hospital Research SiteLocationSite Profile
Centre Jean PerrinClermont-Ferrand, FranceOpen Hospital Dossier ->
Centre Antoine-LacassagneNice, FranceOpen Hospital Dossier ->
CHU PoitiersPoitiers, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI